Premium
Surgery versus stereotactic body radiation therapy for stage I non–small cell lung cancer: A comprehensive review
Author(s) -
Tandberg Daniel J.,
Tong Betty C.,
Ackerson Bradley G.,
Kelsey Chris R.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31196
Subject(s) - medicine , lung cancer , stage (stratigraphy) , radiation therapy , randomized controlled trial , disease , cancer , radiosurgery , surgery , oncology , paleontology , biology
Non–small cell lung cancer (NSCLC) is the leading cause of cancer‐related death in the United States. With the implementation of lung cancer screening, the number and proportion of patients diagnosed with early‐stage disease are anticipated to increase. Surgery is currently the standard of care for patients with operable stage I NSCLC. However, promising outcomes with stereotactic body radiation therapy (SBRT) in patients with inoperable disease has led to interest in directly comparing SBRT and surgery in operable patients. Unfortunately, early randomized trials comparing surgery and SBRT closed early because of poor accrual. In this article, the nuances of surgery and SBRT for early‐stage NSCLC are reviewed. Furthermore, retrospective and prospective analyses of SBRT in early‐stage NSCLC are discussed, and active randomized trials comparing these 2 approaches are described. Cancer 2018;124:667‐78. © 2017 American Cancer Society .